The Association of Affective Resonance With Empathy Modulated by Negative Symptomatology and Oxytocin (OXY)
Schizophrenia Spectrum Disorders
About this trial
This is an interventional treatment trial for Schizophrenia Spectrum Disorders
Eligibility Criteria
Inclusion Criteria:
- Informed consent
- Psychiatric diagnosis from the schizophrenic spectrum (ICD-10: F2x.x spectrum) for group of patients
- Mild to moderate positive symptoms (5 < positive symptoms on individual items using P-PANSS)
- Age: 18 - 65 years
- German should either be the mother tongue or spoken at a native level.
Exclusion Criteria:
- Acute psychotic episode with severe positive symptoms (ICD-10: F2 spectrum, 5 ≥ positive symptoms on individual items using P-PANSS).
- Acute suicidality
- Acute consumption phase of a substance dependence, except nicotine
- No severe physical impairments, neurological diseases and e.g. severe craniocerebral trauma e.g. early childhood brain damage
Sites / Locations
- Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Oxytocin
Placebo
The patients received either a spray of the synthetic oxytocin (24 I.U. Syntocinon®) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.
The patients received either a spray of the synthetic placebo (24 I.U.) with mindfulness-bases grow therapy (MBGT) as a positive social context in each condition. Due to an effect latency of 30-80 mins after intranasal administration of oxytocin on social behavior, the dose was administered 30 min before the 50-min session.